— BNZ-1, a Novel Multi-Cytokine Inhibitor of IL-2/9/15, Demonstrates Favorable Safety and Robust Pharmacodynamic Activity…
Read More
Irvine, CA, December 6, 2017 — Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company leading…
— Favorable Safety, Pharmacokinetics and Robust Pharmacodynamic Activity Demonstrated in Healthy Volunteers- Irvine, CA, July…
Dr. Kaoukhov is the Head of Clinical Development Senior Vice President (SVP), at Bioniz Therapeutics Inc. Dr…
